Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

15.38
-0.3900-2.47%
Volume:996.93K
Turnover:15.35M
Market Cap:1.31B
PE:-4.03
High:15.68
Open:15.68
Low:15.23
Close:15.76
52wk High:62.75
52wk Low:5.95
Shares:85.11M
Float Shares:55.47M
Volume Ratio:0.81
T/O Rate:1.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8139
EPS(LYR):-3.5300
ROE:-67.47%
ROA:-32.44%
PB:3.06
PE(LYR):-4.36

Loading ...

H.C. Wainwright Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Aug 13

MoonLake Immunotherapeutics : H.c. Wainwright Raises Target Price to $50 from $45

THOMSON REUTERS
·
Aug 13

MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital

TIPRANKS
·
Aug 12

Guggenheim Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Aug 11

MoonLake Immunotherapeutics: Files for Mixed Shelf Offering, Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Aug 11

MoonLake Immunotherapeutics Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals

MT Newswires Live
·
Aug 10

MoonLake's Psoriatic Arthritis Drug Meets Key Goals in Late-Stage Trial

Reuters
·
Aug 10

MoonLake Q2 FY26 Net Loss Widens 10.3% to $61.81 Million

Reuters
·
Aug 10

MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16

TIPRANKS
·
Aug 10

MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate

Benzinga Earnings
·
Aug 10

Switzerland's MoonLake Q2 Net Loss Narrows as Expenses Fall

Reuters
·
Aug 10

MoonLake Immunotherapeutics - Blinded Safety Analysis Shows no New Safety Signals for Sonelokimab

THOMSON REUTERS
·
Aug 10

MoonLake Immunotherapeutics - Acr50 Primary Endpoint Met with 42.1% Response for Sonelokimab 60 Mg

THOMSON REUTERS
·
Aug 10

MoonLake Immunotherapeutics - Phase 3 Izar-1 Trial Meets All Clinical Endpoints at Week 16 for 60 Mg Sonelokimab

THOMSON REUTERS
·
Aug 10

MoonLake Immunotherapeutics Q2 EPS USD -0.84

THOMSON REUTERS
·
Aug 10

MoonLake Announces Positive Topline Results from the Phase 3 Izar-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across All Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 10

Press Release: MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across All Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 10

Swiss Stocks - Factors to Watch on August 3

Reuters
·
Aug 03

Moonlake Immunotherapeutics CSO Kristian Reich Disposes of $1 Million in Common Shares

Reuters
·
Jul 24